Nine international pharmaceutical companies, including Sun Pharma of India, have reached pricing agreements with President Donald Trump’s administration to voluntarily bring down the cost of medications in the US to the level of other comparable economies. Other midsize firms, including Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Teva Pharmaceuticals, and UCB, have also inked the agreements.
As it increases its most-favored-nation (MFN) price agreements with 17 major pharmaceutical manufacturers, including Pfizer, AstraZeneca, Merck, Eli Lilly, and Novo Nordisk, Team Trump is putting pressure on modest businesses to comply with its pricing system.
“As of right now, 26 corporations account for 90% of the domestic pharmaceutical sector, with the remaining 10% coming in [to negotiate agreements]. During the announcement, Trump stated, “They have no choice.”
Few details are known about the agreements, which coincide with concerns in the pharmaceutical sector about how price reductions would impact smaller companies’ bottom lines.
But according to the Washington Post, as part of the deal, the pharmaceutical companies will offer MFN pricing to state Medicaid programs and reduce the cost of drugs that treat diseases like hemophilia, glaucoma, Parkinson’s disease, liver disease, and certain types of cancer.
According to the White House, in order to “reduce reliance on foreign nations and ensure the United States has an adequate supply of such products in the event of an emergency,” a number of the companies that signed the agreement, including Astellas Pharma and Sun Pharma, will also be required to donate a significant amount of their products to the Strategic Active Pharmaceutical Ingredients Reserve.
The White House also stated that these businesses have pledged to invest at least $19.6 billion in US manufacturing in the near future.
These businesses are anticipated to stay out of Team Trump’s tariffs and new Medicare prescription pricing schemes in exchange.
-
-
-
-
